Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Current therapy of myelodysplastic syndromes.

    ... approval of azacitidine , decitabine , and lenalidomide in the last decade was a major breakthrough. Nonetheless, the ...

    Research Article last updated 09/03/2013 - 12:03pm.

  2. How we treat lower risk myelodysplastic syndromes.

    ... while anemia of low risk MDS with del 5q responds to Lenalidomide in two thirds of the cases, but this drug should be used ... results have been reported with hypomethylating agents and lenalidomide. Selected patients respond to antithymocyte globulins, while ...

    Research Article last updated 05/14/2013 - 2:56pm.

  3. Recent developments in myelodysplastic syndromes

    ... of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald a new era in the ...

    Research Article last updated 10/02/2014 - 10:30am.

  4. The Myelodysplastic Syndromes: The Era Of Understanding

    ... spite of this, it has become clear that treatment with lenalidomide and azanucleotides can lead to increased overall survival in ...

    Research Article last updated 09/24/2014 - 11:05am.

  5. Update on the pharmacotherapy for myelodysplastic syndromes

    ... drugs for the treatment of these complex malignancies: lenalidomide , azacitidine and decitabine . AREAS ...

    Research Article last updated 08/21/2014 - 9:23am.

  6. Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

    ... report. Abstract # 6522 The FDA approved lenalidomide in 2005 for treatment of lower risk MDS patients (low or ... that a majority of such patients who were treated with lenalidomide achieved sustained independence from RBC transfusions.  Moreover, ...

    Research Review last updated 05/02/2016 - 9:32am.

  7. Molecular pathogenesis of myelodysplastic syndromes

    ... approved therapeutic options for MDS, including lenalidomide , decitabine , and 5-azacytidine, are targeted to ...

    Research Article last updated 05/22/2014 - 10:05am.

  8. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... bone marrow biopsies from 85 patients treated with lenalidomide in the MDS-004 clinical trial were retrospectively ...

    Research Article last updated 04/23/2014 - 12:26pm.

  9. Myelodysplastic syndromes

    ... especially for anaemia, includes growth factors, lenalidomide , and transfusions. Treatment of higher-risk patients is with ...

    Research Article last updated 04/16/2014 - 12:04pm.

  10. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

    ... and del(5q) (P=0.10) cases with controls. Median lenalidomide response duration increased proportionate to C-allele dosage ...

    Research Article last updated 04/08/2015 - 11:21am.